2004
Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635
Bhagwagar Z, Rabiner E, Sargent P, Grasby P, Cowen P. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Molecular Psychiatry 2004, 9: 386-392. PMID: 15042104, DOI: 10.1038/sj.mp.4001401.Peer-Reviewed Original ResearchConceptsMajor depressionDepressed menDepressed subjectsAcute major depressionPositron emission tomography studyPotentials of brainEmission tomography studiesRecurrent major depressionPositron emission tomographyStatistical parametric mappingReceptor BPReference tissue modelAntidepressant medicationPersistent dysfunctionRaphe nucleusUnmedicated subjectsHealthy controlsBP valuesCortical areasTrait abnormalityMale subjectsEmission tomographyPersistent reductionTomography studyReceptor bindingInositol for depressive disorders
Taylor M, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. 2004, 2004: cd004049. PMID: 15106232, PMCID: PMC6984679, DOI: 10.1002/14651858.cd004049.pub2.Peer-Reviewed Original ResearchConceptsTreatment of depressionCochrane Controlled Trials RegisterControlled Trials RegisterTrials RegisterAdjunctive therapyDepressive disorderNeurosis Controlled Trials RegisterCochrane Collaboration DepressionAcceptability of treatmentDouble-blind designShort-term trialsAntidepressant medicationDATA COLLECTIONTherapeutic benefitAlternative treatmentReference listsAffective disordersEffective interventionsTerm trialsAdverse effectsTrialsPoor acceptabilityDepressionTreatmentDisorders
2003
Contrasting effects of citalopram and reboxetine on waking salivary cortisol
Harmer C, Bhagwagar Z, Shelley N, Cowen P. Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology 2003, 167: 112-114. PMID: 12605289, DOI: 10.1007/s00213-003-1417-y.Peer-Reviewed Original ResearchConceptsHPA axis activitySalivary cortisolAxis activitySelective noradrenaline re-uptake inhibitorNoradrenaline re-uptake inhibitorSelective serotonin re-uptake inhibitor citalopramConclusionsShort-term treatmentDifferent antidepressant medicationsHPA axis functionEffect of citalopramRe-uptake inhibitorsDouble-blind designShort-term treatmentBasal salivary cortisol levelsDiurnal salivary cortisolSalivary free cortisolSalivary cortisol levelsAntidepressant administrationRationaleAcute administrationReboxetine treatmentAntidepressant medicationAntidepressant treatmentAxis functionHPA axisAdrenal axisRisperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects
2001
Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low
Rabiner E, Bhagwagar Z, Gunn R, Sargent P, Bench C, Cowen P, Grasby P. Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. American Journal Of Psychiatry 2001, 158: 2080-2082. PMID: 11729033, DOI: 10.1176/appi.ajp.158.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrainDepressive Disorder, MajorDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansMaleMiddle AgedPindololReceptors, SerotoninReceptors, Serotonin, 5-HT1Selective Serotonin Reuptake InhibitorsTomography, Emission-ComputedTreatment OutcomeConceptsPositron emission tomographyDose of pindololClinical trialsDepressed patientsSelective serotonin reuptake inhibitorsSignificant occupancyPresent clinical trialSerotonin reuptake inhibitorsPindolol augmentationAntidepressant medicationReuptake inhibitorsPET evidenceEmission tomographyPindololTrialsDoseAutoreceptorsMedicationsPatientsInconsistent resultsEfficacyVast majorityDoses
1999
Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
Whale R, Bhagwagar Z, Cowen P. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology 1999, 145: 223-226. PMID: 10463324, DOI: 10.1007/s002130051052.Peer-Reviewed Original ResearchConceptsPlasma growth hormoneGrowth hormoneCross-over design studyEffect of ketanserinGrowth hormone responsePathophysiology of depressionGrowth hormone releaseNeuroendocrine probeAntidepressant medicationHealthy menReceptor agonistReceptor subtypesHormone releaseHealthy volunteersBlood samplesNeuroendocrine profilePlasma prolactinAgonist activityHormone responseReceptor functionAssay of prolactinZolmitriptanHormoneOral temperatureMode of action